Overview

Glycine Treatment of Prodromal Symptoms

Status:
Completed

Trial end date:
2004-11-01

Target enrollment:

Participant gender:

Summary

This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Phase:

Phase 2

Details

Lead Sponsor:

Yale University

Collaborator:

Stanley Medical Research Institute

Treatments:

Glycine